Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucravacitinib in Active Psoriatic Arthritis (PsA)
NCT04908189Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2021
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of deucravacitinib in psoriatic arthritis (PsA), sponsored by Bristol Myers Squibb. Started Jul 2021; status: active, not recruiting.
02
Drugs
deucravacitinib
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT04908189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04908189.